Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2020-11-24 M&A Activity
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Grifols ha firmado un acuerdo vinculante (Master Joint Venture Agreement) con la sociedad egipcia National Service Projects Organization para aunar su experiencia industrial y esfuerzos financieros.
M&A Activity Classification · 95% confidence The document is a formal communication from Grifols, S.A., referencing compliance with Article 227 of the Spanish Consolidated Text of the Securities Market Law ('Texto Refundido de la Ley del Mercado de Valores'). It announces a significant business development: signing a Master Joint Venture Agreement (MJVA) with NSPO to develop plasma collection and fractionation facilities in Egypt. This type of announcement, detailing a major strategic transaction (M&A/Partnership) that is not a standard periodic report (like 10-K or IR), falls under the category of material corporate actions or transactions. Given the options, 'M&A Activity' (TAR) is the closest fit for a major joint venture agreement that involves significant capital investment and market expansion, even though it's a JV rather than a pure acquisition/takeover. However, since the core of the document is a major strategic agreement and partnership, and it is being communicated as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information), it is a significant regulatory disclosure. If TAR is strictly for takeovers, the next best fit for major strategic corporate events that aren't standard financial reports is often 'Regulatory Filings' (RNS) as a catch-all for material non-standard news. Given the nature of the agreement (JV for infrastructure development and plasma supply), it is a material event disclosure. Since 'TAR' covers M&A proposals, and this is a major strategic partnership/investment, I will classify it as TAR, as it fundamentally alters the company's operational structure and market approach. The document length is moderate, suggesting it is the primary disclosure, not just an announcement of a report.
2020-11-24 Spanish
FORM 8-K
Regulatory Filings
2020-11-09 English
Como continuación al hecho relevante de fecha 26 de enero de 2018, Grifols informa que ha adquirido el 49% de la compañía Goetech LLC, cuyo nombre comercial es MedKeeper, por el precio de US$ 60,2 mil
M&A Activity Classification · 99% confidence The document is a formal communication from Grifols, S.A. in Spanish, titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It details the acquisition of the remaining 49% stake in MedKeeper for US$ 60.2 million, following an initial 51% acquisition in January 2018. This type of announcement, detailing a significant corporate transaction (acquisition), falls under Merger & Acquisition (M&A) activity. The closest specific category is 'M&A Activity' (Code: TAR). Although it is a direct announcement of the event rather than a link to a larger report, the content is the substance of the M&A event itself, not just a notice that a report is forthcoming. Given the specific nature of the content (acquisition details), TAR is more appropriate than the general fallback RNS or RPA.
2020-11-09 Spanish
FORM 6-K
Regulatory Filings
2020-11-05 English
FORM 6-K
Regulatory Filings
2020-10-21 English
Reunión de inversores y analistas 2020
Investor Presentation Classification · 98% confidence The document is titled "2020 Investor and Analyst Meeting" and contains extensive slides detailing the company's strategy, operations (Bioscience Industrial, Plasma Supply), ESG commitments, and financial impact metrics. It includes forward-looking statements and is clearly designed for presentation to investors and analysts. This format strongly aligns with an Investor Presentation (IP), which typically contains detailed strategic and operational information presented visually, distinct from a formal regulatory filing (like 10-K or IR) or a brief earnings release (ER). The content is too detailed for a simple Fund Factsheet (FS) and is not a transcript (CT) or a formal report (AR/IR).
2020-10-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.